INKT Stock Overview
A clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
MiNK Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.92 |
| 52 Week High | US$1.90 |
| 52 Week Low | US$0.46 |
| Beta | 0.089 |
| 1 Month Change | 35.69% |
| 3 Month Change | 35.89% |
| 1 Year Change | -8.91% |
| 3 Year Change | -74.73% |
| 5 Year Change | n/a |
| Change since IPO | -92.33% |
Recent News & Updates
Recent updates
MiNK Therapeutics (NASDAQ:INKT) Will Have To Spend Its Cash Wisely
Oct 26
Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Deliver On Growth Plans?
Jun 28Is MiNK Therapeutics (NASDAQ:INKT) In A Good Position To Invest In Growth?
Mar 18MiNK Therapeutics GAAP EPS of -$0.18
Aug 16MiNK Therapeutics GAAP EPS of -$0.18
Aug 09MiNK Therapeutics A Bargain For Potential Cell Therapies
Jun 23We're Hopeful That MiNK Therapeutics (NASDAQ:INKT) Will Use Its Cash Wisely
May 05Shareholder Returns
| INKT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 32.0% | 1.9% | 0.7% |
| 1Y | -8.9% | -6.6% | 23.9% |
Return vs Industry: INKT underperformed the US Biotechs industry which returned -7.2% over the past year.
Return vs Market: INKT underperformed the US Market which returned 24.4% over the past year.
Price Volatility
| INKT volatility | |
|---|---|
| INKT Average Weekly Movement | 16.1% |
| Biotechs Industry Average Movement | 11.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INKT's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: INKT's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 31 | Jen Buell | minktherapeutics.com |
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors.
MiNK Therapeutics, Inc. Fundamentals Summary
| INKT fundamental statistics | |
|---|---|
| Market cap | US$35.67m |
| Earnings (TTM) | -US$13.78m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs INKT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INKT income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$13.78m |
| Earnings | -US$13.78m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.35 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -26.3% |
How did INKT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/07 00:16 |
| End of Day Share Price | 2025/01/07 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MiNK Therapeutics, Inc. is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jack Allen | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |